The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

DexCom (NasdaqGS:DXCM) recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose ...

Dexcom stock surged Thursday after the Food and Drug Administration cleared its newest diabetes device for an extended 15-day ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

If you're using a Dexcom G7 to monitor your blood sugar in real-time, you can now sync it to your Apple Watch for real-time ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $100 from $115 and keeps an Outperform rating on the shares as part of a ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

DexCom Inc. closed 51.60% short of its 52-week high of $139.24, which the company achieved on April 25th.

Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, ...